“One-target-one-disease” paradigm has been around for decades, prompting numerous drug discovery programs focusing on identifying small molecules for targeting only …
Personalized medicine has become a paradigm-shifting trend in healthcare - the hegemony of “one-size-fits-all” drugs is increasingly challenged by novel innovative …
Lantern Pharma’s AI-driven drug discovery platform RADR® enables value creation across multiple dimensions of the oncology drug development process: from …
The application of next-generation data analytics tools, powered by machine learning and artificial intelligence (AI) components, has become a long-term …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.